Jade Biosciences (JADE) Doses First Patient in Phase 2 JUNIPER Trial for Kidney Disease Drug

Jade Biosciences (NASDAQ: JADE) dosed the first participant in its Phase 2 JUNIPER trial on May 27, 2026, evaluating JADE 101 for IgA nephropathy (IgAN), a chronic kidney disease with few approved therapies. The milestone advances the company’s lead pipeline candidate into mid-stage testing. The randomized, placebo-controlled study will assess safety, tolerability, and efficacy endpoints including proteinuria reduction. Topline results are expected in the second half of 2027. JADE 101 is designed to target an underlying immune pathway implicated in IgAN progression. The dosing event removes a key regulatory overhang for Jade, offering a concrete timeline for clinical data. Shares were unchanged in premarket trading following the announcement. The company’s pipeline also includes a Phase 1 asset for an inflammatory condition.